BOMBERG
15.7.2021 11:14:08 CEST | Business Wire | Press release
True to its rebellious spirit, BOMBERG has launched the first watch ever to incorporate CBD leaves extract: "BB01 Automatic Cure the BullDog ".
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210715005041/en/
BOMBERG connections to CBD are rooted in the relationship nurtured over the years with dogs.
Since the BOMBERG launch in 2012 the bulldogs, Bolt in Mexico and Duke & Paulina in Switzerland, have always been the official brand ambassadors and mascot.
In 2015 BOMBERG partnered with “Barry Foundation ”, the world’s oldest breeder of St. Bernards and in 2020 with the campaign “Take care of me” supported the “Black Jaguar-White Tiger Foundation ”.
After Bolt suffered an episode of stress, BOMBERG got in touch with “Bouledogue Attitude Foundation ”, in Switzerland, that recommended CBD-based food for its natural properties that help relieve anxiety as well as create a stronger nervous system.
Bolt recovered quickly and helps now spreading the word about BB-01 Automatic Cure the BullDog , the world’s first watch ever containing 100% natural CBD with 0% THC.
Treading an unbeaten path away from the roots of traditional lifestyle industry, BOMBERG embraces the free and insurgent spirit of millions of people around the world who dare to be different and to create their own maverick rules.
The new BB01 Automatic Cure the BullDog combines BOMBERG revolutionary, free and adventurous soul with an outstanding concept and a phenomenal design.
The dial features the instantly recognisable CBD indica plant with its seven serrated leaves and a powerful Super-LumiNova that makes the watch always readable.
BB01 Automatic Cure the BullDog presents real CBD indica leaves extract inside the dial and a strap made of authentic hemp, produced by our partner in the United States, following the strictest sustainability and natural production standards.
BB-01 Automatic Cure the BullDog is the ultimate symbol of audacity signed by BOMBERG .
Technical details:
Reference: |
CT43ASS.30-1.11 |
||
Movement: |
Automatic 3 hands, Sellita SW200, 38 hours power reserve |
||
Case: |
43mm, stainless steel case |
||
|
Outer ring with CBD leaves pattern |
||
Dial: |
Strong Superluminova on the Indica leaf |
||
|
Real organic US hemp inside the dial below the Indica leaf |
||
Crystal: |
Sapphire with anti reflective coating |
||
WR: |
50m |
||
Strap: |
Fabric strap made with US hemp |
||
Buckle: |
Stainless steel folding clasp |
||
|
RRP CHF, VAT excl. CHF 1’790 |
||
|
Quantity SPECIAL EDITION with limited production |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715005041/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Integrates AI into Client Portfolios – Informed by Agentic Technology, Controlled by the Client1.6.2026 16:00:00 CEST | Press release
Clients Can Research Stocks, Analyze Performance, and Generate Trade Instructions in Claude. The Client Approves Every Trade. Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced agentic trading through direct integration with Claude, one of the world's leading AI platforms. Available through the AI platform’s certified connector marketplace, the integration lets clients manage their accounts and access more than 170 global markets. "Interactive Brokers has used technology for over four decades to help investors make more informed decisions and interact more efficiently with markets," said Milan Galik, Chief Executive Officer of Interactive Brokers. "Investors are increasingly using artificial intelligence to research markets, analyze information and generate ideas. We believe the next logical step is to allow clients to securely connect AI tools directly to their brokerage accounts — whether they want a simple conversational interface, deeper portfolio analy
AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 15:01:00 CEST | Press release
AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-
Seoul Semiconductor's World-First 'HV Opto-Semiconductor' Powers Up Global Top 4 Automakers1.6.2026 15:00:00 CEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world's first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world's top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/ Comparison: Conventional 3V LED vs. Seoul Semiconductor 12V 'HV Opto-Semiconductor' (Figure: Seoul Semiconductor) The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplific
Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync™ Series OSA 55101.6.2026 14:00:00 CEST | Press release
News summary: Defense operations require resilient timing architectures that maintain synchronization in contested and GNSS-denied environments ruggedSync™ Series OSA 5510 delivers assured timing and extended holdover in a MIL-qualified platform for tactical, deployable operations Zero-trust resiliency with diversified cPNT sources, including M-Code, PRS and STL, strengthens operational continuity for defense communications, navigation and mission-critical infrastructure Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS suppor
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy1.6.2026 14:00:00 CEST | Press release
- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise. “The Phase 3 RAINIER trial is the largest conducted in IgAN and achieved full enrollment faster than any contemporary IgAN trial, reflecting the significant unmet need in IgAN and our urgency to bring povetacicept to patients with this serious disease,” said Nia Tatsis, Ph.D., Executi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom